The Next Era in U.S. Healthcare Policy & Access Series
Home / Intelligence / Webinars / Policy Change Through Another Lens: Impact on Health Plans and Implications for Biopharma
Available On Demand
The second webinar in our “Next Era in U.S. Healthcare Policy & Access” series looks at the evolving healthcare policy landscape from a different perspective.
Join us as we explore how U.S. policy changes are impacting health plans, how health plan decision-making needs to adapt, and what this means for biopharma companies. The webinar will feature an engaging panel discussion hosted by Max Hunt, Partner at Trinity Life Sciences, with special guests Stephen George and Matthew Hayes, clinical and actuarial experts at Milliman.
Key Webinar Topics
- How have health plans been adapting in light of recent U.S. policy reform, including Part D redesign introduced in the Inflation Reduction Act (IRA)?
- What key opportunities and challenges do health plans face in the next two to three years? How does this differ across Commercial, MA-PD and PDP offerings?
- How should biopharma companies expect that health plan behavior may change in the coming years?
- What challenges may be posed to driving access to innovative drugs, especially in competitive categories?
- What should biopharma companies do to adapt to these landscape shifts and how can they better understand their health plan customers?
In Case You Missed It
Watch the first webinar in our “Next Era in U.S Healthcare Policy & Access Series”
Featuring
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
August 14, 2025 | 12:00 – 12:45 PM ET
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Sign Up Now
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More